Eno : Works in 6 Seconds

Brand : Eno
Company : Glaxo Smithkline Beecham

Brand Analysis Count : # 486

Eno is one of the major players in the Rs 400 crore antacid market. The brand is market leader in the segment closely followed by Gelusil and Digene. Eno is a heritage brand . The brand was born in 1850 created by James Grossely Eno and the product was so successful that  brand immortalized the founder. The brand was acquired by GSK in 1938. Ever since the brand has grown to become a $40 million brand. The brand is currently selling in 34 countries and India features prominent in the list. The brand was launched in India in 1972.

Eno is basically a fruit salt. The brand is special because of its unique powder form. The brand gives immediate relief to problems associated with gastric disorders and indigestion. The brand has been growing very fast in the segment owing to the rise in the lifestyle diseases faced by Indian consumers. Gastric problems are invariably linked to sedentary lifestyle and food habits. The rise in such problems has made the brand grow CAGR of  25% in 2009-10. 

One of the factors that created huge brand equity for Eno is the consistency in positioning.Eno, ever since its launch . The brand's basic promise is " Faster Relief " . What is more interesting is that Eno has quantified the benefit and tells the customer that Eno works with in 6 seconds. These two propositions has created huge brand recall and salience. 

Eno also invested heavily in campaigns. The brand had series of campaign highlighting its unique form and quick relief. One of the disadvantage faced by the brand because of the form was convenience. Since it was in powder form, it is not as convenient as tablets . To counter this, the brand launched Eno tablet in 2004. While the major competitors of Eno were tablets, Eno had the advantage of being fruit based and perceived to be healthy . 

The success of Eno prompted many players like Dr Morepen to enter the market with similar product. But competition could not sustain in the market or could disturb the leadership of Eno. How ever , the brand faced lot of category competition. Gelusil , Digene etc invested heavily in campaigns which gave tough competition for Eno. 

Eno countered this competition by innovating and not being complacent. To increase the choice /variety and to create excitement in the market, the brand launched four different flavors. The brand also introduced another variant which had Pudina as one of the ingredient. The introduction of flavors make the brand more approachable and effectively counters the competition brands like Hajmola. The brand also launched Eno in sachets. In the promotional front, the brand recently tied up with a bollywood movie " Yamla pagla dewaana".

Eno is a brand that did all possible strategies to defend its leadership position.The brand changed with times, introduced variants, invested in promotional campaigns to keep its share of the market. 

Polycrol : Express Relief

Brand : Polycrol
Company : Piramal Healthcare


Brand Analysis Count : # 481

Indian Antacid market is worth around Rs 250 crores and growing at around 10% annually. The market offlate has been witnessing lot of activity with major players running a series of campaign across the media. 

The antacid market consists of prescription products and OTC products. Many brands have crossed over to OTC market to tap the larger potential market. 

Polycrol is a brand from Piramal group that is now launched nationally in the OTC antacid market. The brand which has a 40 year old history is a popular brand in the eastern markets of India. The brand is currently running a series of campaign in the television media.

The Indian antacid market is dominated by brands like Digene, Gelusil, Pudin Hara Eno etc. Digene is mainly a prescription brand while Gelusil is the leading brand in the OTC segment. 

Polycrol has chosen a benefit positioning approach. The brand, like Gelusil, is positioned as a brand that helps people to indulge as a foodie without any fear. But compared to Gelusil, Polycrol was able to execute the positioning in an interesting manner.

Watch the ads here : Polycrol ad 1, Polycrol ad 2 

The brand rightly captured the benefit of the product and conveyed in a simple but effective manner. 

In a marketing perspective, the brand was able to create an awareness through this campaign. Although this brand is in existence for over 40 years, I came to know about this brand only after the current ad campaign. 

Polycrol has entered the market which has brands like Gelusil. Gelusil has unmatched brand awareness and equity in the market. So fighting the leader is not easy for Polycrol.

Through the current campaign, although Polycrol has established awareness, the critical question is How this brand is better /different from other antacid brands ? Since the brand has positioned itself in the same platform as Gelusil, the question of differentiation arises. 

Polycrol is now promoting its nano pack priced at Rs 15 but does not talk much on the differentiation aspect. The thinking is that since Gelusil does not have a credible competitor , creating awareness and parity will drive more sales for the brand. The next step for the brand is to create the point of difference which is credible and sustainable. 

The pack talks about 'Express Relief ' and I think that the brand will be trying to differentiate on that platform.  It will be an interesting brand to watch for .

Crocin : Your Trusted Paracetamol

Brand : Crocin
Company: Glaxo Smithkline
Agency: O&M

Brand Count: 186

Crocin is a three decade old heritage brand. The brand was once generic to the antipyretic category in India . The brand is currently sold through Over The Counter (OTC) route. The brand is the market leader in the paracetamol category.

Crocin was launched in India 30 years ago by the company Duphar Interfran Ltd. During the early years, the brand was marketed through the ethical route. The brand was bought by Smithkline in 1996. The brand was so successful in the market that GSK bought it for a consideration of Rs 45 crore. There was a logic behind the brand acquisition. GSK had the brand Calpol in the prescription market and was a market leader in the Ethical segment. Crocin was proving to be a major threat for Calpol. So the brand was acquired inorder to safeguard the position of Calpol.

The Indian Pharmaceutical market is huge with a valuation of $45 billion. The OTC segment accounts for a value of $ 1 Billion i.e Rs 4500 crore. Crocin is in the analgesic/antipyretic market. The analgesic (pain Killer) market is a large market with a size of Rs 900 crore and the mild analgesic market is worth Rs 300 crore. With in the analgesic market there are two types : Aspirin based and Paracetamol based. Paracetamol based formulations constitute a major part of the market. Crocin formulations has a 5% share in the total market.

Crocin although a generic name in the paracetamol segment faces an interesting problem. 65% of the brand usage is for its antipyretic i.e fever related use. The antipyretic segment in the OTC is very small with a size of Rs 30-40 crore. In the painkiller market which is large, Saridon leads the pack in the OTC segment.

Crocin's market became limited sadly because of its efficacy or popularity as a drug for fever although it had pain killer properties. Sometimes success can become a limiting factor for further growth. The paracetamol segment is witnessing competition from the generic tablets. Most of the time the druggist has the influencing power in the sale of OTC products. During the 1990's if Crocin was a generic name for paracetamol tablets, the situation is different now with consumers asking for Paracetamol rather than Crocin.
Crocin was in the maturity stage of its product lifecycle in 2000 with the sales stagnating.There was intense competition from generic products and other brands.Paracetamol became a commodity with little scope for differentiation. The brand then went into Market Development Mode in 2003 by repositioning the brand as an analgesic. The brand roped in Kapil Dev to endorse the brand. The high profile ad campaign gave a new life to the brand. The brand also came out with variants like Crocin Quik that boasted of faster relief . Quik was essentially a concentrate of the classic Crocin. Crocin also came out with Crocin 1000 aiming at patients having arthritis. Crocin is promoted as an ethical product.

Crocin had its fair share of problems from the " Watch Dogs". Typically when a brand moves from Ethical to OTC and embarks on brand building , there is going to be someone who will cry foul. Crocin faced objections from FDA for some of its campaigns but those were later sorted out.

As far as a customer is concerned, Crocin is still perceived as a drug for fever( antipyretic) rather than as a pain killer(analgesic). It will take a lot of money and time to change that perception.

Related Brands
Gelusil
Vicks
Hajmola

Source: walletwatch,agencyfaqs,pharmabiz

Hajmola : Tasty Funfilled Digestive

Brand : Hajmola
Company: Dabur
Agency: Lowe

Brand Count : 176

Hajmola is one of the power brands from Dabur's portfolio. The brand is one of the oldest and most respected brands in the digestive market in India. The brand commands 75% share in the Rs 90 crore digestive tablet market in India.

Hajmola is a 31 year old brand launched in 1975. The brand has ayurvedic formulation and is sold through all kind of shops unlike the antacids. Hajmola is very popular in North India and North is the strongest market for the brand.
Hajmola although a digestive is not positioned as a digestive brand. The brand has moved away from the therapeutic aspects and is positioned more as a naughty mischievous brand. The brand is positioned as a mild digestive that can be taken any time anywhere. The brand uses kids as the main ambassadors and the campaign that features a boy in the dormitory( Hajmola Sir) is still most remembered classic.

The brand has been nurtured by Dabur carefully. The brand was endorsed by Kapil Dev during 1995.Not restricting itself to tablets, the brand extended itself to candies and other forms of digestives. Now Hajmola has Candy, Candy Fun2, Mast Masala and Hajmola Yumshell. The brand also has changed its package from the old rustic glass bottle to a new contemporary pack. Dabur has now promoted Hajmola as an umbrella brand in the digestive segment .The brand is now worth Rs 100 crore.

In 2004 Dabur roped in Amitabh Bachchan to endorse all Dabur power brands. Hajmola also got the power of Big B into its fold. The ads now feature the fun filled tussle between Big B and a kid. Hajomola has kept its positioning of being a fun filled product. The reason for not restricting to digestive is to give the brand more room for growth. If positioned entirely as a digestive, the usage of brand will be limited. Hence Hajmola tries to induce the customers to take it anytime anywhere. In all the campaigns the brand is positioned on its Zingy Zangy taste (Khatta Meeta).
The brand has also ventured into the highly competitive candy market . The hard boiled candy market is estimated to be around Rs 350 crore and Hajmola is reported to have a 9% market share.
Hajmola has always tried to focus on the Northern market. The ads are predominately Hindi and not at all targeting the south market . The tagline of Hajmola " Hazm Sab, Chahe Jab" will not be understood by most South Indians. The brand is also not being promoted heavily in this market. One reason can be that the taste of Hajmola may not suit the South Indian Palate.

Like the Chawanprash market , the digestive market also feels the issue of stagnation. The endorsements by celebrities and the heavy spending are the only way out for brands facing such stagnation issues.

Related Brands
Gelusil
Sona Chandi

source: dabur.com, agencyfaqs,businessline,magindia,domainb

Gelusil : Ye kam kare to aap kam kare

Brand: Gelusil
Company: Pfizer
Agency: Contract

Brand Count:105

Gelusil is one of the major brands in the 220 crore antacid market in India . A brand once owned by Parke-Davis came into Pfizers hand when the two companies merged. Gelusil was promoted through ethical route where the drugs are to be sold only through prescription. This 30 year old brand had a strong support from the medical community and is worth Rs 20 crore.

In 1999 Gelusil became the first antacid brand to shift from ethical route to OTC. It was a risky move since there was a chance of alienating the medical practitioners and also doubts about the ad spent that is needed to promote such a mass market product.

The antacid market in India is crowded with lot of products fighting for their share of the pie. The market leader is Digene from Abbot Pharma with a market share of 35% followed by Eno from GSK with 24% , Gelusil with 21% and Pudin Hara with 14%. Digene is still sold through the ethical route and are available only at the Chemists. Eno and Pudin Hara are available in all shops since they are ayurvedic products.

Globally antacids are sold as OTC products. The market is expected to grow faster in India because of the " changed" lifestyle of less exercise and more junk foods. Right now in the OTC segment, growth is now taken more by the ayurvedic products rather than products like Gelusil because of the association of " no side effects" with ayurvedic products.

Gelusil faced a setback in 2004 when Pfizer had to recall its liquid form because of odour problem. Gelusil have some issues with its taste as it may not be liked by some of the customers ( including me). For that matter all antacids tastes bad. Since this product is now sold through OTC, the share of mind and share of voice is crucial for maintaining and building market share. The creatives of Gelusil were critically acclaimed with one ad winning at the ABBY's.

With a huge potential for antacids in the future, Gelusil has to get more aggressive to leap from the solid foundation it had created .

Source: Businessline, agencyfaqs, magindia, companywebsite.